Leuko is developing the world's first non-invasive device, PointCheck, to monitor white blood cells.
PointCheck can detect low neutrophil levels in patients without blood extraction. This allows for remote monitoring, which makes the test suitable to prevent febrile neutropenia, a life-threatening complication of chemotherapy. This disruptive technology uses novel optics and software that acquire and analyse videos of capillary microcirculation.
PointCheck offers a competitive advantage through its convenience due to its unique optical non-invasive technology. No other device, either on the market or in development, compares with PointCheck, in terms of convenience or non-invasiveness.